Fund moves

Angiodynamics (ANGO): Divisadero Street Capital Management, LP added to its stake +445K shares

Divisadero Street Capital Management, LP added to its stake in Angiodynamics, per its Q1 2025 13F.

960K
Shares reported · +445K vs prior quarter
0.91%
Disclosed portfolio weight
$9.02M
Reported value
Holdings as of
Mar 31, 2025
Filed
May 15, 2025

What stands out in this filing

  • 514,635 shares in Q4 2024, 960,065 now (+86.6% in share count).
  • Reported at $9.02M, 0.91% of the portfolio value in this 13F filing.
  • No other tracked manager reported the same kind of change for Q1 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

    What came next

    1. Jun 27, 2025CongressDisclosed purchase of ANGO — reported range $1,001 - $15,000
    2. Jul 16, 2025CongressDisclosed sale of ANGO — reported range $1,001 - $15,000
    View the official recordSEC Form 13F-HR

    How to read SEC Form 13F-HR

    Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

    Full guide: What is an SEC Form 13F?

    What else is on file for Angiodynamics

    For Angiodynamics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

    These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANGO page.

    How this filing works

    Explore the data

    Common questions

    What does this filing report about Angiodynamics (ANGO) stock?

    Divisadero Street Capital Management, LP added to its stake in Angiodynamics, per its Q1 2025 13F. Now 960K shares, $9.02M reported value, 0.91% of disclosed portfolio.

    When did it happen, and when was it made public?

    Holdings as of: Mar 31, 2025. Filed: May 15, 2025.

    What stands out in this filing?

    514,635 shares in Q4 2024, 960,065 now (+86.6% in share count). Reported at $9.02M, 0.91% of the portfolio value in this 13F filing. No other tracked manager reported the same kind of change for Q1 2025.

    Is this a trade made on a known date?

    No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

    Where does this information come from?

    From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

    What else has been disclosed about Angiodynamics recently?

    For Angiodynamics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the ANGO page.

    Does this mean ANGO stock is a buy or a sell?

    No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

    Is OQRO free?

    Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

    Other disclosures at Angiodynamics

    Everything OQRO holds on this company is on its ANGO page.

    This is one filing. OQRO holds the rest

    Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

    OQRO is free for everyone. No card, no trial

    OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data